Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494-1506. doi:10.3324/haematol.2019.243543
Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ. The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011;6:33. Published 2011 Apr 12. doi:10.1186/1746-1596-6-33
Davis MM. A new trigger for T cells. Cell. 2002;110(3):285-287.
Kuhns MS, Davis MM, Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. Immunity. 2006;24(2):133-139.
Sjödahl G, Lövgren K, Lauss M, et al. Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol. 2014;32(6):791-797.
Rathore AS, Kumar S, Konwar R, et al. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res. 2014;140(3):361-369.
Fang C, Zhuang Y, Wang L, et al. High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia. Cancer Sci. 2013;104(8):996-1001.
Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009;113(16):3773-3780.
Bagacean C, Quintin-Roue I, Ianotto JC, et al. CD20 negative relapse of a follicular lymphoma after chemoimmunotherapy. HVM Bioflux 2015;7:302-305.
Amedei A, Della Bella C, Silvestri E, et al. T cells in gastric cancer: friends or foes. Clin Dev Immunol. 2012;2012:690571.
Tian C, Lu S, Fan Q, et al. Prognostic significance of tumor-infiltrating CD8⁺ or CD3⁺ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer. Chin Med J (Engl). 2015;128(1):105-110.
Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-213.
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
